Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients

[1]  R. Serra,et al.  Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease , 2015, International wound journal.

[2]  R. Larson,et al.  Cilostazol is associated with improved outcomes after peripheral endovascular interventions. , 2014, Journal of vascular surgery.

[3]  F. Perosa,et al.  Raynaud's phenomenon: from molecular pathogenesis to therapy. , 2014, Autoimmunity reviews.

[4]  D. Prati,et al.  Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost , 2012, Rheumatology International.

[5]  A. Moorthy,et al.  Diagnosis and management of Raynaud’s phenomenon , 2012, BMJ : British Medical Journal.

[6]  G. Valentini,et al.  [HAQ-DI Italian version in systemic sclerosis]. , 2011, Reumatismo.

[7]  S. Negrini,et al.  Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. , 2011, Clinical immunology.

[8]  N. Chattipakorn,et al.  Effects of cilostazol in the heart , 2011, Journal of cardiovascular medicine.

[9]  A. Kamal,et al.  Cilostazol Versus Aspirin for Secondary Prevention of Vascular Events After Stroke of Arterial Origin , 2011, The Cochrane database of systematic reviews.

[10]  M. Cutolo,et al.  Brachial Artery Endothelial-dependent Flow-mediated Dilation Identifies Early-stage Endothelial Dysfunction in Systemic Sclerosis and Correlates with Nailfold Microvascular Impairment , 2010, The Journal of Rheumatology.

[11]  M. Baumhäkel,et al.  Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Recent Achievements in the Management of Raynaud's Phenomenon , 2022 .

[12]  T. Levien.  Advances in the treatment of Raynaud’s phenomenon , 2010, Vascular health and risk management.

[13]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[14]  L. Pearce,et al.  Cilostazol and peripheral arterial disease , 2008 .

[15]  Sung-Hwan Park,et al.  Elevated matrix metalloproteinase-9 in patients with systemic sclerosis , 2004, Arthritis research & therapy.

[16]  R. Brook,et al.  Effects of cilostazol in patients with Raynaud's syndrome. , 2003, The American journal of cardiology.

[17]  Richard W. Martin,et al.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. , 2002, Arthritis and rheumatism.

[18]  T. Medsger,et al.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. , 1997, Arthritis and rheumatism.

[19]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[20]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[21]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[22]  Dong-mei Jin,et al.  Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. , 2012, Atherosclerosis.